Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data

Meir Schechter; Cheli Melzer Cohen; Tamir Zelter; Ilan Yanuv; Aliza Rozenberg; Gabriel Chodick; Avraham Karasik; Ofri Mosenzon

doi:10.1111/dom.15172

Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data

Meir Schechter, Cheli Melzer Cohen, Tamir Zelter, Ilan Yanuv, Aliza Rozenberg, Gabriel Chodick, Avraham Karasik, Ofri Mosenzon

Tel Aviv University

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	3054-3058
Number of pages	5
Journal	Diabetes, Obesity and Metabolism
Volume	25
Issue number	10
DOIs	https://doi.org/10.1111/dom.15172
State	Published - Oct 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1111/dom.15172

Cite this

Schechter, M., Melzer Cohen, C., Zelter, T., Yanuv, I., Rozenberg, A., Chodick, G., Karasik, A., & Mosenzon, O. (2023). Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data. Diabetes, Obesity and Metabolism, 25(10), 3054-3058. https://doi.org/10.1111/dom.15172

@article{72aa04d79cc84986a2f9f8812bea8b6c,

title = "Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data",

author = "Meir Schechter and \{Melzer Cohen\}, Cheli and Tamir Zelter and Ilan Yanuv and Aliza Rozenberg and Gabriel Chodick and Avraham Karasik and Ofri Mosenzon",

note = "Funding Information: This was an investigator‐initiated project. The study was funded by Boehringer Ingelheim. The funder was involved in study design by means of providing nonbinding scientific expert advice and approved this report. This report was written by the investigators and the decision to submit for publication was made solely by the investigators.",

year = "2023",

month = oct,

doi = "10.1111/dom.15172",

language = "الإنجليزيّة",

volume = "25",

pages = "3054--3058",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "John Wiley and Sons Inc.",

number = "10",

}

Schechter, M, Melzer Cohen, C, Zelter, T, Yanuv, I, Rozenberg, A, Chodick, G, Karasik, A & Mosenzon, O 2023, 'Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data', Diabetes, Obesity and Metabolism, vol. 25, no. 10, pp. 3054-3058. https://doi.org/10.1111/dom.15172

Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data. / Schechter, Meir; Melzer Cohen, Cheli; Zelter, Tamir et al.
In: Diabetes, Obesity and Metabolism, Vol. 25, No. 10, 10.2023, p. 3054-3058.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease

T2 - Real-world data

AU - Schechter, Meir

AU - Melzer Cohen, Cheli

AU - Zelter, Tamir

AU - Yanuv, Ilan

AU - Rozenberg, Aliza

AU - Chodick, Gabriel

AU - Karasik, Avraham

AU - Mosenzon, Ofri

N1 - Funding Information: This was an investigator‐initiated project. The study was funded by Boehringer Ingelheim. The funder was involved in study design by means of providing nonbinding scientific expert advice and approved this report. This report was written by the investigators and the decision to submit for publication was made solely by the investigators.

PY - 2023/10

Y1 - 2023/10

UR - http://www.scopus.com/inward/record.url?scp=85164185328&partnerID=8YFLogxK

U2 - 10.1111/dom.15172

DO - 10.1111/dom.15172

M3 - رسالة

C2 - 37385956

SN - 1462-8902

VL - 25

SP - 3054

EP - 3058

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 10

ER -

Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this